Clinical Trials Browser

Phase 2 × Recruiting × Parkinson Disease 4, Autosomal Dominant Lewy Body × Clear all

NCT07252739 2026-03-16

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT06788912 2026-03-10

MK-3475-01E

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Lung Neoplasms

NCT06961006 2026-03-09

INTerpath-012

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT06780085 2026-02-19

MK-3475-01H

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT05941338 2023-07-12

HNC-SYSU-001

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Mouth Neoplasms

NCT04812002 2022-06-03

Study of PD-1 Antibody and Bevacizumab in the Treatment of High-risk GTN After Combined Chemotherapy

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Gestational Trophoblastic Disease

NCT03753243 2022-04-20

Neoadjuvant Pembrolizumab Plus Androgen Axis Blockade Prior to Prostatectomy for High Risk Localized Prostate Cancer

Phase 2 Recruiting

Parkinson Disease 4, Autosomal Dominant Lewy Body, Prostatic Neoplasms